An observational study in Abdominal Aortic Aneurysm, sponsored by American Heart of Poland. Recruiting at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by American Heart of Poland · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Aortic Aneurysm, Abdominal with a site in Poland — 6 open to participants now, 6 under way, none of them phase 3. Aortic Aneurysm, Abdominal · Poland.
Among the 15 studies in Aortic Aneurysm, Abdominal with a site in Poland, this one is the only one that started in 2026, is one of 8 observational ones, and was the 15th registered.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
Browse Aortic Aneurysm, Abdominal studies →6 of the 15 studies in Aortic Aneurysm, Abdominal with a site in Poland are open now. Recruiting first, the newest first:
W.L.Gore & Associates · Sites in Poland, United States, Australia and 10 more countries
Ages 18+
Samodzielny Publiczny Szpital Kliniczny nr 2 PUM · Sites in Poland
Ages 18+
John Paul II Hospital, Krakow · Sites in Poland
Ages 18–85
FCRE (Foundation for Cardiovascular Research and Education) · Sites in Poland, United States, Austria and 7 more countries
Ages 18+
Grena Biomed Limited · Sites in Poland, Belgium
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 165 across 217 observational studies indexed under Aortic Aneurysm, Abdominal.
Median enrollment 87 across the 7 interventional studies, 201 across the 8 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 15 have an industry lead sponsor. The 10 most frequent:
American Heart of Poland is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
American Heart of Poland has 1 study filed under Aortic Aneurysm, Abdominal — fewer than ten, so there is no comparison to draw.
2 of the studies in Aortic Aneurysm, Abdominal with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07476196American Heart of PolandPoland-Italy Aortic Research Bridge Real World Registry | 2027-03-31 |
| NCT06969729Samodzielny Publiczny Szpital Kliniczny nr 2 PUMEvaluation of Clinical Efficacy and Safety of Aortal Stent-Graft Created Using 3D Printing Technology | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Aortic Aneurysm, Abdominal with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Objective To pragmatically collect and analyze patient-level clinical, procedural, and outcome data from participating centers in Italy and Poland on the use of the PERCUTEK Tycheseal™ stent-graft system for the endovascular repair of abdominal aortic aneurysms. The study aims to generate high-quality, real-world evidence on the technical success, safety, and mid-term outcomes of the device.
Study Design This is a pragmatic, observational, multicenter physician-initiated registry that will collect patient-level data for all eligible patients undergoing PERCUTEK Tycheseal™ device implantation. Each site will enter data into a standardized paper case report form (CRF), including demographic, anatomical, procedural, and follow-up variables. Sites will be expected to comply with data entry timelines and quality control checks. The total projected enrollment is 120-200 patients across all sites over an expected 18 month inclusion period.
The target enrollment is 120-200 patients across all participating sites.
Background and Rationale
Abdominal Aortic Aneurysm (AAA): Clinical Burden and Unmet Needs Abdominal aortic aneurysm (AAA) is a progressive and potentially fatal vascular disease defined as a localized dilatation of the abdominal aorta exceeding 1.5 times its normal diameter, typically ≥3.0 cm. The pathophysiology of AAA involves complex interplay between genetic predisposition, chronic inflammation, extracellular matrix degradation, and biomechanical wall stress. Risk factors for AAA include advanced age, male sex, smoking, hypertension, dyslipidemia, and family history. Notably, population based screening studies have shown that up to 5-8% of men over the age of 65 harbor asymptomatic AAAs, many of which are at risk of expansion and eventual rupture if left untreated. The clinical importance of timely diagnosis and treatment of AAA lies in its natural history: once the aneurysm reaches a critical threshold-commonly 5.5 cm in diameter in men or 5.0 cm in women-the risk of rupture increases substantially. Aneurysm rupture is associated with extremely high mortality, with up to 90% of patients dying before reaching the hospital or during emergency intervention. Consequently, elective repair is indicated in appropriately selected patients based on aneurysm size, growth rate, symptomatology, and anatomical feasibility.
Advances and Challenges in Endovascular Aneurysm Repair (EVAR) Over the past two decades, endovascular aneurysm repair (EVAR) has largely supplanted open surgical repair (OSR) as the preferred modality for treating infrarenal AAA in anatomically suitable patients. EVAR offers several perioperative advantages, including reduced operative blood loss, shorter procedure times, lower 30-day mortality rates, and faster postoperative recovery. These benefits make EVAR especially attractive for elderly patients and those with significant comorbidities who may not tolerate open surgery.
Despite these advantages, EVAR is not without limitations. Long-term surveillance is required due to risks of late complications such as graft migration, endoleak formation (particularly types I and III), aneurysm sac expansion, and device thrombosis. These complications may necessitate secondary interventions and contribute to long-term morbidity. Additionally, anatomical constraints such as short or highly angulated necks, calcification, thrombus burden, and tortuous iliac arteries may preclude the safeuse of some endograft systems. As a result, device selection plays a crucial role in procedural success and long-term outcomes.
The Poland-Italy Aortic Research Bridge Real World Registry (POWER) is a pragmatic, observational, multicenter registry designed to systematically collect real-world data on the use of the PERCUTEK Tycheseal™Tri-Modular Endograft System in patients undergoing endovascular repair of abdominal aortic aneurysms (AAA).
Study Type This is a non-randomized, open-label, post-market physician-initiated clinical investigation. It does not involve experimental treatments or random allocation of interventions, and no comparator arm is included.
Objectives
Participating Countries and Sites
Estimated Enrollment
Each subject will be followed for up to 24 months post-implantation, with assessments at baseline, discharge, 1 month, 12 months and 24 months.
The PERCUTEK Tycheseal™Endograft System: Design Rationale The PERCUTEK Tycheseal™ system is a tri-modular stent graft platform designed for the treatment of infrarenal AAA. It consists of a main body and two iliac limb components, each optimized for precision deployment, modular adaptability, and enhanced seal zone conformity. The device is intended to address common anatomical challenges by accommodating a wide range of aortic neck diameters (main body proximal graft diameters: 20-36 mm, with 10-20% of oversizing), tolerating moderate angulation (up to 75°), and facilitating reliable fixation and sealing even in anatomically complex patients.
The PERCUTEK Tycheseal™ system features a low-profile delivery system, radiopaque markers for fluoroscopic visibility, and graft materials engineered for biocompatibility and durability. Early use in single-center case series and preliminary feasibility studies suggests that the device offers favorable deliverability, short procedure duration, and high technical success. However, robust, pragmatic, multicenter data in real-world settings are still lacking, which limits broader confidence in its long-term safety and performance.
Rationale for the POWER Registry The Poland-Italy Aortic Research Bridge Real World Registry (POWER) has been established to pragmatically evaluate the use of the PERCUTEK Tycheseal™ stent graft system in a real-world clinical environment across multiple high-volume European centers. This physician-initiated registry aims to fill a critical evidence gap by generating longitudinal, patient-level data on technical feasibility, clinical outcomes, and device-related complications over a 12-24- month period.
Several compelling factors justify the need for this registry:
Through detailed documentation of implantation success, early and mid-term complications, and follow-up imaging, the POWER Registry will support an evidencebased understanding of the PERCUTEK Tycheseal™system's performance. The use of standardized paper CRFs, centralized data coordination, and optional site-level aggregate submissions ensures a flexible yet rigorous data capture approach. Ultimately, the POWER Registry aligns with contemporary regulatory and clinical imperatives for post-market device surveillance, and its findings are expected to directly contribute to the refinement of EVAR indications, device iteration, and patient centered care in AAA management.
Patients with abdominal aortic aneurysm
Anatomical Inclusion Criteria (as per IFU):
Patient Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Technical success of the PERCUTEK Tycheseal™ stent-graft implantation, defined as successful deployment at the intended site with the absence of immediate type I or III endoleaks and no requirement for unplanned conversion to open repair.
Time frame: 12 months
Freedom from aneurysm sac enlargement, defined as no increase ≥5 mm in the maximum transverse aortic aneurysm diameter at 12 months compared to baseline imaging.
Time frame: 12 month
Freedom from type I or III endoleaks, confirmed by Doppler ultrasound or angio CT at the 6- and 12-month follow-ups.
Time frame: 6 and 12 months
Freedom from aneurysm rupture during the 12-month follow-up period.
Time frame: 12 months
Freedom from stent-graft migration resulting in a serious adverse event or requiring secondary intervention.
Time frame: 12 months
Freedom from any stent-graft occlusion at 12 months.
Time frame: 12 months
Aneurysm-related mortality at 12 months
Time frame: 12 months
All-cause mortality
Time frame: 30 days; 12 months
Aneurysm sac regression >5 mm at 12 months compared to baseline.
Time frame: 12 months
Major adverse events (MAEs) at 30 days, 12 months, and 24 months, including: Myocardial infarction, Stroke or transient ischemic attack, New-onset renal failure or dialysis requirement.
Time frame: 30 days; 12 months; 24 months
All endoleaks (types I, II, III, or undefined origin) detected at 30 days, 12 months, and 24 months.
Time frame: 30 days; 12 month; 24 months
Reinterventions, categorized as: For treatment of endoleaks, For stent-graft thrombosis or occlusion.
Time frame: 24 months
Serious adverse device effects (SADEs) throughout the study period.
Time frame: 24 months
Device performance metrics as rated by implanting physicians (e.g., ease of use, trackability, radiopacity).
Time frame: 24 months
Medication adherence, particularly antiplatelet and anticoagulant regimens.
Time frame: 24 months
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
Of 67 non-industry observational studies under Aortic Aneurysm, Abdominal, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 83. This study's planned 12 months is below that.
Counting every sponsor, half of 91 studies reached it within 48 months; a quarter within 24 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
American Heart of Poland